Related Experiment Video

Updated: Oct 22, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K

Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options

Caterina Mancarella1, Andrea Morrione2, Katia Scotlandi1

  • 1Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.

Cells
|August 27, 2021
PubMed

Insights

Aberrant insulin-like growth factor (IGF) signaling drives cancer. Combinatorial therapies targeting the complex IGF system are needed for better sarcoma treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The insulin-like growth factor (IGF) system plays a critical role in cancer development and progression.
  • Targeted therapies against the IGF system show potential but have limited clinical efficacy in sarcomas due to molecular complexity.
  • Understanding IGF system dysregulation is crucial for developing effective cancer treatments.

Purpose of the Study:

  • To review mechanisms of IGF system dysregulation in cancer.
  • To analyze the IGF system's impact on sarcoma development, progression, and therapy response.
  • To explore novel therapeutic combinations by understanding IGF system interactions.

Main Methods:

  • Literature review of preclinical and clinical studies on the IGF system in cancer.
  • Analysis of molecular pathways interacting with the IGF system in sarcomas.
  • Discussion of therapeutic strategies targeting the IGF axis.

Main Results:

  • IGF system dysregulation is a key driver in various cancers.
  • Limited clinical benefit of anti-IGF therapies in sarcomas highlights the need for complex therapeutic strategies.
  • Ephrin receptors, Hippo pathway, BET proteins, and CXCR4 signaling are identified as key interactors with the IGF system in tumor cells.

Conclusions:

  • The molecular complexity of the IGF system necessitates combinatorial therapeutic approaches for effective cancer treatment, particularly in sarcomas.
  • Investigating interactions between the IGF system and pathways like Ephrin receptors, Hippo, BET, and CXCR4 can inform novel treatment strategies.
  • A deeper understanding of these molecular networks may lead to more effective therapeutic combinations for sarcomas.
Keywords:
BET proteinsCXCR4 signalingEphrin receptorsHippo pathwayIGF inhibitorsIGF systemcombined treatmentssarcomas

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.9K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
771
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K